Mathias Werner

Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial

Neyssa Marina, Sigbjørn Smeland, Stefan Bielack et al. · The Lancet Oncology · 2016 · 511 citations · Full text

Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial

Stefan Bielack, Sigbjørn Smeland, Jeremy Whelan et al. · Journal of Clinical Oncology · 2015 · 412 citations · Full text

Long-term results of the co-operative German–Austrian–Swiss osteosarcoma study group’s protocol COSS-86 of intensive multidrug chemotherapy and surgery for osteosarcoma of the limbs

N. Fuchs, Stefan Bielack, D. Epler et al. · Annals of Oncology · 1998 · 346 citations · Full text

Intensive Multidrug Chemotherapy, Protocol Coss-86, Surgical Oncology +7

Evaluation of neoadjuvant therapy response of osteogenic sarcoma using FDG PET.

M. Schulte, D. Brecht‐Krauss, Mathias Werner et al. · PubMed · 1999 · 205 citations

The influence of tumor- and treatment-related factors on the development of local recurrence in osteosarcoma after adequate surgery. An analysis of 1355 patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols

Dimosthenis Andreou, Stefan Bielack, D. Carrle et al. · Annals of Oncology · 2010 · 150 citations · Full text

Surgical Oncology, Adequate Surgery, Medicine +9